Summary & Overview
HCPCS J3111: Injection, romosozumab-aqqg, 1 mg
HCPCS Level II code J3111 denotes a 1 mg injection of romosozumab-aqqg, a monoclonal antibody used to treat osteoporosis by promoting bone formation and reducing resorption. As a high-cost biologic therapy administered by injection, this code is relevant for outpatient infusion centers, physician offices, and specialty practices managing osteoporosis.
Key national payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage policies, prior authorization requirements, and site-of-care stipulations for romosozumab vary across these payers and can affect access and billing workflows.
Readers will find a concise overview of the clinical context for romosozumab, the billing implications of using HCPCS Level II code J3111, and what to expect in payer interactions and claims adjudication. The publication covers benchmark considerations, relevant policy updates affecting injectable biologics, and operational notes for outpatient settings. Data not available in the input will be noted explicitly where applicable.
Billing Code Overview
HCPCS Level II code J3111 represents an injection of romosozumab-aqqg, billed per 1 mg. This code describes administration of a monoclonal antibody therapy used in the treatment of osteoporosis by inhibiting sclerostin to increase bone formation and decrease bone resorption.
Service type: Drug administration (injectable biologic)
Typical site of service: Outpatient infusion/injection center or physician office
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a postmenopausal woman with osteoporosis at high risk for fracture who presents to an outpatient infusion or specialty clinic for administration of romosozumab-aqqg. The clinician (often an endocrinologist, rheumatologist, or specialized osteoporosis nurse/physician assistant) confirms diagnosis, reviews bone mineral density results and prior fracture history, and verifies that the patient has no hypocalcemia or recent myocardial infarction or stroke. The injection is administered subcutaneously as a monthly treatment, with monitoring for injection-site reactions and potential cardiovascular events. Documentation includes indication, informed consent, date and time of administration, lot number and amount of drug (in mg), route (subcutaneous), site (e.g., left or right abdomen or thigh), any immediate adverse reactions, and follow-up plan for subsequent monthly doses. Billing uses the HCPCS Level II code J3111 reported per milligram as described by the product labeling and payer rules; appropriate modifier(s) are appended when relevant (for example, to indicate a reduced service, a discontinued service, or Medicare-specific status). Typical sites of service include outpatient infusion centers, physician offices, and specialty clinics.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Administrative delivery of a service (placeholder for some payers) | When a payer requires an internal modifier indicating an initial or primary service per payer rules (use sparingly per payer guidelines) |